Bli medlem
Bli medlem

Du är här

2017-02-06

uniQure Announces Presentations at Upcoming February Conferences

ing February Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, 2017-02-06 13:00 CET (GLOBE
NEWSWIRE) --
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced
presentations at the following conferences taking place in February:

Leerink Partners 6th Annual Global Healthcare Conference, at the Lotte New York
Palace Hotel in New York City

-- Matthew Kapusta, chief executive officer, will participate in a Fireside
Chat on Wednesday, February 15th at 3.00 p.m. EST. The live webcast can be
accessed by the link displayed in the Investor section of the uniQure
website at: http://uniqure.com/investors-newsroom/overview.php. The webcast
replay will be available for at least 72 hours following the live event.

61st Annual Meeting of Society of Thrombosis and Hemostatis Research at the
Congress Center in Basel, Switzerland

-- Professor Wolfgang Miesbach, M.D. professor of hematology at the University
of Frankfurt, Germany and an investigator in the ongoing Phase 1-2 clinical
trial of AMT-060 (AAV5 hFIX) gene transfer in adult patients with severe
hemophilia B, will present previously disclosed interim results from the
dose escalating study on Thursday, February 16th at 15.00 CET/ 09.00 a.m.
EST.

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and validated
technology platform to rapidly advance a pipeline of proprietary and partnered
gene therapies to treat patients with hemophilia, Huntington’s disease and
cardiovascular diseases. www.uniQure.com

uniQure Contacts:

Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452
m.cantor@uniQure.com

Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541
t.malone@uniQure.com

Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
e.mulder@uniQure.com

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.